Celltrion Pharm is at risk of being designated as a business corporation unfaithful in public disclosure for failing to make public its planned merger with Celltrion Group.The Korea Exchange on Wednesday said it would review designating Celltrion Pharm as an unfaithful public announcement corporatio
LG Chem's recent land purchase from a U.S. biotech firm is garnering attention due to speculations about the potential construction of a biopharmaceutical manufacturing plant. LG Chem said nothing has been decided yet.BioProcess International, a U.S. publication that covers bioprocessing, reported o
NeoImmuneTech said Monday that it would present two poster presentations of clinical and nonclinical studies on NT-I7 (efineptakin alfa) at the Society for Immunotherapy of Cancer (SITC), which will be held from Nov. 1-5 in San Diego, Calif.In an animal cancer model, the triple combination of NT-I7,
Samsung Biologics said it expected to post annual sales of more than 3.6 trillion won this year, up more than 20 percent from the previous year.In a public filing on Thursday, Samsung Biologics said it has raised its annual sales growth outlook for 2023 by more than 20 percent, instead of the previo
TiumBio announced on Sunday the fourth-quarter global clinical trial updates for its lead pipelines, including its endometriosis drug candidate TU2670.TiumBio is currently conducting a phase 2a clinical trial of TU2670 in endometriosis patients in Europe, with plans to generate European top-line dat
Daewoong Bio, whose flagship products include choline alfoscerates, is entering the health-functional food business.Industry executives watch with interest whether the company could find a new path, overcoming the crisis caused by reduced health insurance benefits for choline alfoscerates.Daewoong B
Celltrion said it has received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for Yuflyma, a biosimilar referencing Humira (ingredient: adalimumab).Humira, the original medicine, is prescribed primarily for autoimmune diseases such as rheumatoid arthritis, inflammatory b
Lotte Biologics said Thursday that CEO Lee Won-jik visited Lithuania on the northeastern Baltic Sea coast to seek cooperation in the bio industry.According to Lotte Biologics, Lee attended and delivered a keynote speech at the “Life Science Baltics” event in Vilnius, the capital of Lithuania, on Wed
HLB has formalized its decision to move from the tech-heavy Kosdaq market to the main exchange of the Kospi market, entering into the shifting process.Industry watchers pay attention to see if HLB, known as the "Kosdaq bellwether," can complete its listing on the Kospi market.HLB said in a public fi
In a strategic move to strengthen its global position, SK pharmteco announced its acquisition of the US-based cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), The Center for Breakthrough Medicines (CBM).With this acquisition, SK pharmteco plans to emerge as a l
U.S. biopharmaceutical company Rani Therapeutics has embarked on a phase 1 clinical trial of oral ustekinumab (RT-111) using Celltrion's Stellara biosimilar CT-P43.In January, Celltrion agreed with Rani to develop oral ustekinumab and adalimumab (Humira). Celltrion will develop its antibodies as ora
HLB said Monday that its U.S. subsidiary, Elevar Therapeutics, will attend the European Society for Medical Oncology (ESMO) 2023 in Madrid from Oct. 20 to 24 to discuss partnerships with leading European pharmaceutical companies for the distribution and sale of rivoceranib in Europe.Eleva will run a
Genome&Company recently initiated a phase 2 clinical trial for biliary tract cancer by combining MSD's immune checkpoint inhibitor Keytruda (pembrolizumab) with its immuno-oncology candidate GEN-001.Industry insiders are watching with interest what results Genome&Company will achieve as it targets s
Samsung Biologics said it has signed a $242 million contract manufacturing organization (CMO) contract with Swords Laboratories, a subsidiary of Bristol-Myers Squibb (BMS), to manufacture immunotherapy treatment until 2030.Samsung Biologics emphasized that this contract highlights the significant ro
Korean biotech companies participated in the first summit of CancerX, the first CancerX activity since the organization's launch. However, observers said it would likely take time for the participating companies' R&D activities to get in full swing.The Inaugural CancerX Member Summit was held on Thu
Celltrion Group Chairman Seo Jung-jin met with overseas investors and institutional stakeholders to present the blueprint for the group's merger and future vision.Seo attended the 21st Morgan Stanley Global Healthcare Conference in New York City, U.S., on Sep. 11 (local time), and shared the group's
An artificial intelligence-based prostate cancer diagnosis aid developed by a Korean company has received marketing authorization from overseas regulators, attracting the industry’s attention.Deep Bio said Tuesday that its AI-based prostate cancer diagnostic auxiliary software, DeepDx Prostate, rece
LifeSemantics said Tuesday it has decided to increase its capital by 20 billion won ($15 million) at its board of directors meeting.After shareholder allocation, the capital increase will be conducted as a public offering of forfeited shares. The first subscription will be for existing shareholders
Samsung Bioepis said it has entered into a commercialization agreement with Sandoz for SB17, a proposed biosimilar for Stelara (ingredient: ustekinumab), for North America and Europe.Stelara was developed by multinational pharmaceutical company Janssen, the pharmaceutical arm of Johnson & Johnson (J
In a recent development regarding corporate trade secrets, Samsung Biologics has achieved a partial victory in its lawsuit against three former employees who moved to Lotte Biologics. The company accused the former employees of breaching trade secrets.According to Money Today, a local news outlet, t